Ano Kaisha no Shikumi
Search
Menu

Teva Pharmaceutical Industries Limited

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Key figures

Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP

RevenueDisclosed US$17.3B
Operating marginCalculated 12.5%
Net assets to total assetsCalculated 19.4%

Company profile

Ticker TEVA / CIK 818686 / Chemicals and pharmaceuticals (SIC 2834) / Fiscal year end 2025-12-31
U.S. GAAP. From the Form 10-K filed with the SEC’s EDGAR.

Tables scroll sideways

Disclosed data

Source: U.S. SEC annual report (Form 10-K) (Jan 2025 to Dec 2025) · filed 2026-02-03

Profitability ★★★☆☆position among all companies 12.5%
Growth (revenue, 4-year average) ★★☆☆☆position among all companies 2.1%
Capital efficiency ★★★★☆position among all companies 17.8%

Revenue and profit

Performance, financial position and capital allocation

Teva Pharmaceutical Industries Limited

Recent performance trends

17 11 4 -2 4 years ago 3 years ago 2 years ago Last year This year Net sales Operating income US$ billion

Teva Pharmaceutical Industries Limited

Cash flow trends

2 0 -1 -2 4 years ago 3 years ago 2 years ago Last year This year Operating CF Investing CF Financing CF US$ billion
Consolidated indicators (9 items)
Item4 years ago3 years ago2 years agoLast yearThis year
Net sales US$15.9 billion US$14.9 billion US$15.8 billion US$16.5 billion US$17.3 billion
Operating income US$1.7 billion US$-2.2 billion US$0.4 billion US$-0.3 billion US$2.2 billion
Net income US$0.4 billion US$-2.4 billion US$-0.6 billion US$-1.6 billion US$1.4 billion
Total assets US$47.7 billion US$44.0 billion US$43.5 billion US$39.3 billion US$40.7 billion
Shareholders' equity US$10.3 billion US$7.8 billion US$7.5 billion US$5.4 billion US$7.9 billion
Net cash provided by (used in) operating activities US$0.8 billion US$1.6 billion US$1.4 billion US$1.2 billion US$1.6 billion
Net cash provided by (used in) investing activities US$1.5 billion US$0.7 billion US$1.0 billion US$0.8 billion US$0.7 billion
Net cash provided by (used in) financing activities US$-2.2 billion US$-1.5 billion US$-1.9 billion US$-1.8 billion US$-2.2 billion
Cash and cash equivalents US$2.2 billion US$2.8 billion US$3.2 billion US$3.3 billion US$3.6 billion

Revenue scale in the same industry

Teva Pharmaceutical Industries Limited

Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed

Sources and methodology

Basic indicators
ItemValueConsolidated / Non-consolidatedSource
Purchase of property, plant and equipment US$0.5 billion ConsolidatedDisclosed
Cash and cash equivalents US$3.6 billion ConsolidatedDisclosed
Net cash provided by (used in) financing activities US$-2.2 billion ConsolidatedDisclosed
Net cash provided by (used in) investing activities US$0.7 billion ConsolidatedDisclosed
Net cash provided by (used in) operating activities US$1.6 billion ConsolidatedDisclosed
Depreciation and amortization US$1.0 billion ConsolidatedDisclosed
Stockholders' equity (including non-controlling interests) US$7.9 billion ConsolidatedDisclosed
Non-controlling interests US$4.00 million ConsolidatedDisclosed
Net assets US$7.9 billion ConsolidatedDisclosed
Net sales US$17.3 billion ConsolidatedDisclosed
Operating income US$2.2 billion ConsolidatedDisclosed
Net income US$1.4 billion ConsolidatedDisclosed
Total assets US$40.7 billion ConsolidatedDisclosed
Operating margin 12.5%ConsolidatedCalculated
Net assets to total assets 19.4%ConsolidatedCalculated
Net margin 8.2%ConsolidatedCalculated
Return on equity 17.8%ConsolidatedCalculated
How to read the figures, and caveats

Terms

  • Consolidated: the parent company together with the subsidiaries it consolidates
  • Parent-only: the single company that filed the annual securities report
  • Calculated: a disclosed figure put through the formula shown
  • Not disclosed: no such value in the filing (not treated as zero)
  • Not retrieved: a value this page could not extract, including values in the filing that could not be matched. The same item may appear in another table
  • Segment: a business division the company uses in its disclosures
  • Industry median: the middle value among companies in the same industry that disclose the item
  • ★: position when every company is lined up by value (not a judgement of the company)See the formulas
  • Source: document name, period covered, filing date and where it was obtained
  • Tables scroll sideways

Key figures

  • Operating margin 12.5%　Operating income ÷ revenue 　＝ US$2.2 billion ÷ US$17.3 billion
    The denominator is revenue under U.S. GAAP (consolidated, U.S. GAAP).
  • Net assets to total assets 19.4%　Stockholders' equity ÷ total assets 　＝ US$7.9 billion ÷ US$40.7 billion
    Calculated here from stockholders' equity and total assets (no equity-to-asset ratio disclosed by U.S. companies; the Japanese field is the company's own disclosed value)
  • Net margin 8.2%　Net income ÷ revenue 　＝ US$1.4 billion ÷ US$17.3 billion
  • Return on equity 17.8%　Net income ÷ stockholders' equity 　＝ US$1.4 billion ÷ US$7.9 billion
    Calculated here (not a value the company disclosed)

Cash flow trends

  • Cash flow (change in cash and cash equivalents) by activity. Operating CF: cash generated by the business. Investing CF: asset purchases, disposals and acquisitions. Financing CF: borrowing, repayments, dividends and share repurchases. Negative: net outflow

Revenue scale in the same industry

  • Revenue (disclosed values) of companies in the same industry, using the same grouping as the industry pages. Only the top three and the two companies either side of this one. Bar length relative to the largest company (100). An order of size, not a ranking of quality

Data sources and calculation methods

Primary source: the SEC’s EDGAR: Form 10-K of TEVA PHARMACEUTICAL INDUSTRIES LIMITED (CIK 818686), free to read
Accounting standard: U.S. GAAP / Form: 10-K / Filed: 2026-02-03 / Accession number: 0001193125-26-034532

  • Amounts: machine transcription of XBRL filed with the SEC’s EDGAR (bulk companyfacts), no manual re-keying. In dollars, not converted to yen (an exchange rate would produce a figure that was never disclosed)
  • Annual values: full-year figures in the Form 10-K only. Where a restatement gives more than one value for a period, the more recently filed one. Each five-year series from a single element (tag)
  • Revenue: the company’s elements checked in the order Revenues → RevenueFromContractWithCustomer… → SalesRevenueNet, taking the one with the most recent period. What “revenue” covers may differ between companies
  • Net income: attributable to the parent’s shareholders. Stockholders’ equity: excluding non-controlling interests (the figure including them on a separate row)
  • ★: position of values calculated from disclosed figures among U.S. companies, on a five-step scale. Separate from Japanese companies because of different accounting standards. Finance (SIC 6000s) in its own set, as revenue is defined differently
  • Equity-to-asset ratio: no rank (higher or lower is not better or worse). Calculated here as stockholders’ equity ÷ total assets, as U.S. companies do not disclose it (for Japanese companies the field is the company’s disclosed value). Return on equity also calculated here
  • Industry: first two digits of the SEC’s SIC code. A different classification from the Japanese industry categories (FSA), so shown separately from Japanese companies
  • Segment breakdown, profit-and-loss flow and cost breakdown: not published (bulk companyfacts holds company-wide figures only). Nothing drawn from guesswork
  • Share prices: not used. Employee counts: only where the 10-K XBRL carries them as a number